CRSP — Crispr Therapeutics AG Share Price
0.000.00%
Last trade - 00:00- $4.03bn
- $2.03bn
- $371.21m
- 60
- 20
- 39
- 34
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.03 | ||
| Price to Tang. Book | 2.03 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 19.93 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -16.03% | ||
| Return on Equity | -14% | ||
| Operating Margin | -175.38% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 289.59 | 0.72 | 914.96 | 1.2 | 371.21 | 49.74 | 288.12 | 160% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Directors
- Rodger Novak CHM (53)
- Samarth Kulkarni CEO (42)
- Brendan Smith CFO (46)
- Lawrence Klein COO (38)
- James Kasinger GCN (49)
- Philippe Drouet OTH
- Ali Behbahani IND (44)
- Bradley Bolzon IND (61)
- Simeon George IND
- John Greene IND (55)
- Katherine High IND (69)
- Douglas Treco IND (63)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- October 31st, 2013
- Public Since
- October 19th, 2016
- No. of Shareholders
- 17
- No. of Employees
- 407
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 85,168,158
- Address
- Baarerstrasse 14, ZUG, 6300
- Web
- https://crisprtx.com/
- Phone
- +41 415613279
- Contact
- Susan Kim
- Auditors
- Ernst & Young LLP
Upcoming Events for CRSP
Q3 2024 CRISPR Therapeutics AG Earnings Release
Q4 2024 CRISPR Therapeutics AG Earnings Release
Q4 2024 CRISPR Therapeutics AG Earnings Release
Similar to CRSP
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
FAQ
What is the Crispr Therapeutics AG share price?
As of Today at 20:07 UTC, shares in Crispr Therapeutics AG are trading at $47.32. This share price information is delayed by 15 minutes.
How has the Crispr Therapeutics AG share price performed this year?
Shares in Crispr Therapeutics AG last closed at $47.32 and the price had moved by +3.45% over the past 365 days. In terms of relative price strength the Crispr Therapeutics AG share price has underperformed the S&P500 Index by -22.69% over the past year.
What are the analyst and broker recommendations for Crispr Therapeutics AG?
The overall consensus recommendation for Crispr Therapeutics AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Crispr Therapeutics AG dividend yield?
Crispr Therapeutics AG does not currently pay a dividend.
Does Crispr Therapeutics AG pay a dividend?
Crispr Therapeutics AG does not currently pay a dividend.
When does Crispr Therapeutics AG next pay dividends?
Crispr Therapeutics AG does not currently pay a dividend.
How do I buy Crispr Therapeutics AG shares?
To buy shares in Crispr Therapeutics AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Crispr Therapeutics AG?
As of the previous close price of $47.32, shares in Crispr Therapeutics AG had a market capitalisation of $4.03bn.
Where are Crispr Therapeutics AG shares listed?
Here are the trading details for Crispr Therapeutics AG:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CRSP
What kind of share is Crispr Therapeutics AG?
Based on an overall assessment of its quality, value and momentum Crispr Therapeutics AG is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Crispr Therapeutics AG share price forecast for 2024?
The analyst consensus target price for shares in Crispr Therapeutics AG is $81.21. That is 71.62% above the last closing price of $47.32.
Analysts covering Crispr Therapeutics AG currently have a consensus Earnings Per Share (EPS) forecast of -$5.69 for the next financial year.
Find out moreWhat is the trend in the Crispr Therapeutics AG share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Crispr Therapeutics AG. Over the past six months, its share price has underperformed the S&P500 Index by -36.56%.
As of the last closing price of $47.32, shares in Crispr Therapeutics AG were trading -21.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Crispr Therapeutics AG PE Ratio?
The Crispr Therapeutics AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $47.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Crispr Therapeutics AG?
Crispr Therapeutics AG's management team is headed by:
- Rodger Novak - CHM
- Samarth Kulkarni - CEO
- Brendan Smith - CFO
- Lawrence Klein - COO
- James Kasinger - GCN
- Philippe Drouet - OTH
- Ali Behbahani - IND
- Bradley Bolzon - IND
- Simeon George - IND
- John Greene - IND
- Katherine High - IND
- Douglas Treco - IND